Navigation Links
Human Genome Sciences Advances Oncology Portfolio
Date:4/16/2008

AP (inhibitor of apoptosis) proteins, is expected to enter Phase 1 clinical trials for the treatment of cancer by mid-2008. In addition, HGS has substantial financial rights to certain products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS-ETR1, HGS-ETR2 or other HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securit
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 06, 2015 The Remedy ... growth strategy for the specialty pharmacy industry, will be ... 2015 Armada Specialty Pharmacy Summit. The Summit will be ... Las Vegas and is the largest annual gathering for ... in attendance, from pharmacy providers, pharma/biotech manufacturers, and payers, ...
(Date:5/5/2015)... 2015  23andMe, Inc., the leading personal genetics company, ... Study in collaboration with Pfizer Inc. The companies ... more commonly known as lupus, into the study to ... is also in collaboration with the Lupus Research Institute, ... Approximately 1.5 million people in the U.S. ...
(Date:5/5/2015)... 5, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... continue trading on OTCQB  Marketplace, the market for ... allows for a continuous public market for trading ... real-time quotes and market information on us through ... Marketplace includes U.S. and international companies in venture ...
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
Breaking Biology Technology:The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... March 13 Proteon Therapeutics, Inc.,( http://www.proteontherapeutics.com ... first-in-class pharmaceuticals to address the,medical needs of ... appointed,Gregory D. Phelps, a seasoned biopharmaceutical executive, ... brings more than 30 years of executive,leadership ...
... Lead Candidate HspE7 into Phase 2 Clinical Trial in ... ... Nventa Biopharmaceuticals,Corporation announced today financial results for the year ended December,31, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO ), During 2007, the Company achieved the ...
... FAIRFIELD, New Jersey, March 13, "The new Stonegate ... as the only biopharma company that,manufactures peptides by ... systems to administer the peptides. Since the launch ... has,captured a near dominant 49% market share of ...
Cached Biology Technology:Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7Stonegate Report About Unigene Laboratories Inc. 2Stonegate Report About Unigene Laboratories Inc. 3Stonegate Report About Unigene Laboratories Inc. 4Stonegate Report About Unigene Laboratories Inc. 5Stonegate Report About Unigene Laboratories Inc. 6Stonegate Report About Unigene Laboratories Inc. 7Stonegate Report About Unigene Laboratories Inc. 8Stonegate Report About Unigene Laboratories Inc. 9Stonegate Report About Unigene Laboratories Inc. 10
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... typically viewed as detrimental, plant pathologists with the American ... successful, eco-friendly tool for managing weeds. , ... is considered as one of the alternative weed control ... of chemical herbicides is not permitted or feasible," said ...
... was used to help monitor the health of Florida's coral ... August and September. , The project was the first comprehensive ... Marine Sanctuary that stretches about 300 miles from Martin County ... trying to determine why some reefs are resilient to environmental ...
... of malaria hits pregnant women and children the hardest. A ... in Uganda has now produced some important findings on how ... falciparium is the name of by far the most virulent ... particularly dangerous in that it also infects the placenta of ...
Cached Biology News:Fight weeds with plant pathogens 2NASA satellite data helps assess the health of Florida's coral reef 2NASA satellite data helps assess the health of Florida's coral reef 3New findings could lead to vaccine for severe malaria 2
... Doublestain System is a high-sensitivity peroxidase ... The kit is intended for use ... of two different antigens within the ... suitably diluted rabbit and mouse primary ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... VAMP-2 (Vesicle-Associated Membrane Protein 2, ... not share homology with any ... It is expected that the ... human, Macaca multata and bovine ...
... locus encodes two unrelated proteins both of ... the cell cycle in a p53-dependent manner. ... rapid degradation of mdm2 proteinrequired for mdm2 ... This interaction is mediated by the ...
Biology Products: